FDA action against supplier’s Greek facility forces production halt and prompts revision of Cipla’s financial outlook
New York, United States, 10 March 2026 – Cipla USA Inc. has initiated a recall of several batches of its Lanreotide injection in the United States, creating a temporary shortage of the product in the market. The recall follows regulatory action taken by the U.S. Food and Drug Administration (FDA) against Pharmathen International S.A., the company’s exclusive manufacturing partner for the drug.
The FDA classified Pharmathen’s manufacturing facility in Rodopi, Greece, as “Official Action Indicated” after an inspection in November 2025. During the inspection, regulators identified multiple concerns related to contamination risks and issues in aseptic manufacturing processes. As a result, production at the facility has been halted until the company completes corrective actions and receives regulatory clearance.
Lanreotide injection is one of Cipla’s key pharmaceutical products in the U.S. market, used in the treatment of certain hormonal disorders and rare tumors. The drug holds approximately 22 percent of the market share in its category, making it an important contributor to the company’s international revenues.
The disruption in supply has also affected Cipla’s financial outlook. The company recently revised its operating margin guidance for the fiscal year to around 21 percent, down from its earlier projection of 22.5 percent. This marks the second downward revision in the current financial year, reflecting the impact of supply chain challenges and regulatory setbacks.
Industry analysts note that the situation highlights the risks associated with relying heavily on a single supplier for critical pharmaceutical products. When regulatory actions or manufacturing issues occur, they can quickly disrupt supply chains and affect product availability in key markets.
The U.S. market for Lanreotide is highly competitive, with other pharmaceutical companies offering similar treatments. One of the most widely known products in this category is Somatuline, developed by Ipsen, which holds a significant share of the market.
For Cipla, the current situation could create temporary revenue pressure, particularly because Lanreotide has been one of its largest products in the U.S. portfolio. The company has also indicated that its fourth-quarter performance may be affected due to reduced sales from Lanreotide and another key drug, generic Revlimid.
Cipla’s management is currently working closely with Pharmathen to address the manufacturing issues and implement necessary corrective measures. The company hopes production can resume once regulatory approval is obtained. While Cipla has expressed optimism about restarting production later in the fiscal year, some industry experts believe the recovery process could take longer, potentially extending into early fiscal year 2027.
Despite the short-term challenges, the situation highlights the importance of strong pharmaceutical supply chain management, regulatory compliance, and diversified manufacturing partnerships in the global healthcare industry.
